Selling a Plastic Surgery Practice in 2026: Multiples, Named Buyers, and the Operator Playbook

If you own a plastic surgery practice in 2026, the M&A market is thinner than other healthcare-services subsegments. Most plastic surgeons operate cosmetic-cash-pay solo practices with high owner-MD personal-brand dependency — which compresses transferability and limits the buyer pool. SkinSpirit (Leonard Green Partners) operates the largest US MedSpa + aesthetic + light surgical platform. Sono Bello (Aurora Capital Partners) is body-contouring focused. PE-backed platforms (Skytale, Cortes NLD, Plastic Surgery Partners, Aesthetic Centers of America) continue selective regional rollups but face the structural transferability challenge.

What the asset is worth depends on three things: (1) MedSpa + skincare integration (recurring revenue beyond one-time surgical cases), (2) surgical case mix and MD provider bench (multi-MD is premium to solo), and (3) surgical suite ownership with accreditation and modern operating infrastructure. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

This guide is about plastic surgery practices (MD-surgical, primarily cash-pay cosmetic). For non-surgical aesthetic clinics (injectables, laser, body contouring without surgery), see our separate guide at how to sell a MedSpa. For medical + surgical dermatology (Mohs, cosmetic dermatology), see how to sell a dermatology practice.

Named plastic surgery / aesthetic M&A transactions (2022-2025)

The named buyer landscape

PE-backed national platforms

• SkinSpirit (Leonard Green Partners) — the largest US MedSpa + aesthetic + light surgical platform. Selective on surgical acquisitions; primarily MedSpa-focused.
• Sono Bello (Aurora Capital Partners) — body-contouring focused (BodyTite, Smart Lipo, microaire); ~80+ centers nationally.
• Skytale Group (PE) — aesthetic-heavy, some surgical platform exposure.
• Cortes NLD (PE) — aesthetic-heavy.
• Plastic Surgery Partners (PE-backed) — regional platform.
• Aesthetic Centers of America (PE-backed) — regional.
• American Surgical Professionals (private) — multi-state.

PE sponsors active in this space

• Leonard Green Partners (SkinSpirit), Aurora Capital Partners (Sono Bello), Skytale Group, NewSpring Capital, plus multiple aesthetic-services PE funds.

The transferability challenge

• Most plastic surgeons operate cosmetic-cash-pay solo practices with high owner-MD personal-brand dependency. The buyer pool is structurally smaller than dermatology or ophthalmology because plastic surgery patients often follow the surgeon personally, not the practice. This compresses multiples and limits the achievable scale for any single platform.

What each buyer will pay for vs. what they reject

• Will pay premium for: MedSpa + skincare revenue integration (recurring revenue beyond one-time surgical cases), multi-MD provider bench (reduces single-surgeon dependency), surgical suite ownership with AAAASF or Joint Commission ambulatory accreditation, diversified case mix (breast aug, tummy tuck, facelift, mommy makeover, body contouring, rhinoplasty), modern EMR (PatientNow, Symplast, Aesthetic Record), named referral relationships.
• Will compress or reject: single-MD owner-brand dependence (the structural challenge), pure surgical without MedSpa integration, no surgical suite ownership or suite-rental dependence, legacy operating systems, weak provider bench, weak documented before/after revenue continuity for any acquired practice.

The operator-level KPI playbook buyers will diligence

Service-line mix

• Surgical case mix: Breast augmentation, breast reduction, tummy tuck (abdominoplasty), facelift, blepharoplasty, rhinoplasty, mommy makeover, body contouring (lipo), gynecomastia.
• MedSpa revenue: Injectables (Botox, fillers), laser, Hydrafacial, skin care.
• Skincare retail revenue.
• Reconstructive (insurance-paid) vs. cosmetic (cash-pay) mix.
• Average revenue per surgical case by type.

Surgical suite and ASC

• Owned surgical suite vs. hospital/ASC rental.
• Accreditation: AAAASF, Joint Commission ambulatory, or state office-based surgery licensure.
• Case volume per surgical suite.
• Anesthesia model: CRNA, anesthesiologist, hospital provided.

MD provider bench

• Provider count and tenure.
• Provider compensation model.
• Provider patient transferability: Documented patient retention when an MD leaves.
• Patient-to-provider matching analytics.

Payer mix

• Cash-pay percentage: Most plastic surgery is cash-pay; track cash mix.
• Patient financing partners: CareCredit, Alphaeon Credit, PatientFi, GreenSky.
• Insurance-paid reconstructive percentage.

Marketing and brand

• Patient acquisition mix: Direct website, social media (Instagram dominant), referrals.
• Marketing spend as % of revenue.
• Cost of customer acquisition (CAC).
• Practice brand strength.

EMR and operating system

• EMR: PatientNow, Symplast, Aesthetic Record, Touch MD, Nextech.
• Photo management: Before/after photo library integrated.
• Patient consultation workflow.

Dangers and traps in plastic surgery M&A

1. Owner-MD personal-brand dependency (the structural challenge)

Most plastic surgery patients follow the surgeon personally. The single-MD-owner-brand-dependent practice has limited transferability and compresses to the lowest multiples. Build the MD bench 2-3 years before sale.

2. Surgical suite ownership vs. rental

Owned surgical suite (AAAASF or Joint Commission accredited) provides facility-fee revenue and is a multiple-builder. Suite-rental dependence creates uncertainty.

3. Marketing spend dependency

If practice CAC is high (10%+ of revenue) and marketing engine is owner-personal-brand-driven, that’s a structural risk.

4. State office-based surgery (OBS) regulations

State-specific OBS regulations (especially Florida, New York) affect surgical-suite operations. Document compliance.

5. Patient financing partner concentration

Heavy dependence on a single financing partner (e.g., CareCredit) creates risk if terms change.

6. Pure surgical without MedSpa integration

Pure surgical practices have higher per-case revenue but no recurring revenue. MedSpa + skincare integration adds recurring revenue and multiple-builder economics.

7. Complication and litigation history

Plastic surgery has higher malpractice exposure than other specialties. Document complication rates, settled matters, and current insurance coverage.

8. Equity-rollover and earnout expectations

PE-MSO plastic surgery deals often include 30-50% equity rollover plus multi-year earnouts to mitigate transferability risk.

Our POV on plastic surgery M&A in 2026

Plastic surgery is the thinnest M&A subsegment within aesthetics/healthcare-services because of the owner-MD personal-brand transferability challenge. SkinSpirit (Leonard Green Partners) is the dominant integrated platform. PE-backed platforms (Sono Bello, Skytale, Cortes NLD, Plastic Surgery Partners) continue selective rollups but face the structural transferability constraint. Multiples thinner than dermatology and ophthalmology.

Preparing your plastic surgery practice for sale: 12-18 months out

1. Get multi-year audited or reviewed financials. Document case mix and revenue per case.
2. Build the MD provider bench. Reduce owner-MD personal-brand dependence; this is the highest-leverage pre-sale work.
3. Integrate MedSpa + skincare revenue. Add recurring revenue beyond one-time surgical cases.
4. Document surgical suite accreditation. AAAASF, Joint Commission ambulatory, or state OBS.
5. Diversify patient financing partners.
6. Modernize EMR. PatientNow, Symplast, Aesthetic Record.
7. Document complication rates and malpractice history.
8. Document marketing engine and CAC.
9. Run a competitive process. SkinSpirit (Leonard Green), Sono Bello (Aurora Capital), Skytale Group, Cortes NLD, Plastic Surgery Partners, Aesthetic Centers of America, plus PE sponsors directly.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a plastic surgery practice in 2026?

Single-MD cosmetic practices ($500k-1.5M SDE) typically sell at 2.5x-4x SDE. Multi-MD single-site or 2-3 location practices ($1.5-4M EBITDA) go 3.5x-5x. Small regional groups ($3-8M EBITDA) go 4x-6x. Mid-size platforms with MedSpa integration ($5-15M EBITDA) go 5x-8x. Premium scale platforms ($15M+ EBITDA, multi-state, surgical + MedSpa + skincare integrated, named provider bench) reach 7x-10x+.

Who are the active buyers of plastic surgery practices right now?

PE-backed national platforms: SkinSpirit (Leonard Green Partners, largest US MedSpa + aesthetic + light surgical), Sono Bello (Aurora Capital Partners, body-contouring focused), Skytale Group (PE), Cortes NLD (PE), Plastic Surgery Partners (PE), Aesthetic Centers of America (PE), American Surgical Professionals. PE sponsors: Leonard Green Partners, Aurora Capital Partners, Skytale Group, NewSpring Capital.

Why is plastic surgery M&A thinner than other healthcare-services subsegments?

Most plastic surgery patients follow the surgeon personally, not the practice brand. This creates an owner-MD personal-brand transferability challenge that is structurally larger than in dermatology, ophthalmology, or other specialties. The buyer pool is smaller because acquired practice value depends heavily on the selling surgeon remaining engaged post-close. PE-MSO deals in plastic surgery often include 30-50% equity rollover and multi-year earnouts to mitigate this risk.

What hurts a plastic surgery practice’s valuation most?

Single-MD owner-brand dependence (the structural challenge), pure surgical without MedSpa or skincare integration, no surgical suite ownership, suite-rental dependence, legacy operating systems, weak provider bench, weak documented before/after revenue continuity, high marketing CAC dependence on owner personal-brand, and complication/malpractice history.

How is selling a plastic surgery practice different from selling a MedSpa or dermatology practice?

Plastic surgery is MD-surgical (cosmetic + reconstructive), with most revenue from one-time surgical cases at $5,000-$25,000+ per case. MedSpa is non-surgical aesthetic services (injectables, laser, Hydrafacial) with smaller per-visit revenue but recurring patient base. Dermatology is medical + surgical (Mohs, cosmetic). Each has distinct buyer pools, regulatory considerations, and multiple profiles. See our separate guides for MedSpa and dermatology.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.

How long does it take to sell a plastic surgery practice?

Once you go to market with a buyer-paid advisor, a typical process runs 5-9 months from initial outreach to closing. Add 12-18 months of preparation work before going to market.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. Highest-leverage pre-sale work: build the MD provider bench (reduce owner-MD personal-brand dependence), integrate MedSpa + skincare revenue, document surgical suite accreditation, modernize EMR, and document complication rates.

Related research

• How to sell a MedSpa
• How to sell a dermatology practice
• How to sell an ophthalmology practice
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell an imaging center
• How to sell a clinical laboratory
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch